A NEW ERA...Fox Chase President and CEO Richard I. Fisher, MD, (third from left) prepares for a day in the clinic with his hematologic oncology team. Since Richard I. Fisher, MD, took

POWERFUL COLLABORATIONSannual report 2014

A NEW ERA

Cancer is as varied and complex as human beings. Its path in eachpatient is completely distinct. How we go about preventing, treating,and coping with cancer can differ based on factors that range fromour genes to our cultural heritage. Because of this perpetual variation,scientists and clinicians make the most progress in understandingcancer when they combine their knowledge and collaborate acrossprocesses and biological systems.

Fox Chase has had a collaborative culture since our earliest days.Today, that culture, expanded through our affiliation with TempleUniversity Health System, positions us especially well to acceleratethe discoveries researchers are making every day here andworldwide. In this review of 2014, you will see that it is the freshmeeting of minds that has marked our most exciting advances andthat holds the promise of a new era in cancer care.

IN CANCER CARE

1FOX CHASE CANCER CENTER ANNUAL REPORT 2014

Q&A WITH THE CEO

2 POWERFUL COLLABORATIONS

Fox Chase President and CEO Richard I. Fisher, MD, (third from left) prepares for a day in the clinic with his hematologic oncology team.

Since Richard I. Fisher, MD, took the helm as president and CEO of Fox Chase in July 2013,he has helped Fox Chase build on its strengths by recruiting talented new scientists andclinicians to join our ranks. He has also pursued new avenues of growth, working closelywith Temple colleagues to maximize the gains from our affiliation with the Health System.

Why does collaboration hold the keys to progress in cancer care today?

Throughout the world, science ismoving so fast and is so complicatedthat no single lab or individual has all thetechnical capacity and knowledgeneeded to move us forward. Individualresearchers make their most meaningfulcontributions in the context of teamscience. The teams that care for patientsmust also reflect multiple differentdisciplines in order to deliver treatmentthat is right for each individual.

What makes Fox Chase especially well positioned to lead in this era?

Fox Chase’s early leaders alwaysemphasized collaboration, across labsand across generations. That spirit hasbecome fundamental to the culture here.Senior scientists take the time to mentoryounger faculty members as well asfellows and students. Even our physicalstructure supports collaboration, withour labs and treatment facilities all inone place. Just moving around the hallsand eating together in the cafeteria, ourscientists and clinicians becomeintellectually engaged in each other’swork.

What is different about the current emphasis at Fox Chase?

What is new is the degree to whichwe are bringing the clinical piecetogether with bench science. We arevery excited that Wafik El-Deiry, aphysician and scientist, has joined us asdeputy director for translationalresearch, precisely to accelerate thismovement. El-Deiry is a well-establishedresearch leader who has taken sciencefrom his own lab to clinical settings. Hehas also formed two companies tospeed the application of scientificadvances to patient care. It’s an excitingtime at Fox Chase. It’s a time when ourtradition of collaborative learning andrespect for various disciplines is cominginto its own, to the benefit of science asa whole and, most important, ourpatients.


Numbers represent Fiscal Year 2014

89,240 outpatient visits

7,599 patients

394 clinical trials

25 new faculty members

20%increase in totalphilanthropicsupport

22%increase in scientificpublications

One of 41

treatment centersnationally designateda ComprehensiveCancer Center by the NCI

Top 20 for cancer careby U.S. News &World Report

2014by the numbers

GOING WHERE THE PEOPLE ARE


Grace Ma, PhD, (left) and Carolyn Fang, PhD, (third from left) meet with their outreach staff at the Center for Asian Health.

Carolyn Fang, PhD, Fox Chase associate professor, and Grace Ma, PhD, professor anddirector of the Center for Asian Health at Temple’s College of Health Professions andSocial Work, collaborate with each other—and with the community—to study andreverse the factors driving up rates of cancer among Asian Americans.

Although the Korean-Americanwoman was well into her 50s, she hadnever had a Pap test. “Why should I gosee a doctor when I feel fine?” she askedthe community health educator who hadrecommended cervical screening.

She is the exact type of person GraceMa and Carolyn Fang want to reachthrough Temple’s Center for AsianHealth, which aims to unravel whycancer is prevalent in certain Asian-American populations—and to stop itsspread. Even though cancer is theleading cause of death among AsianAmericans, they remain the nation’sleast studied population in the areas ofcancer prevention and control.

When it came time for the woman’sPap test, it turns out she was not fine.After receiving abnormal results,navigators from the Center for AsianHealth connected her to the appropriatefollow-up care. “I wouldn’t have knownwhat to do or where to go,” she says.

a health partnershipAs the Center helps more Asian

Americans in Philadelphia get the healthcare they need, these same men andwomen are contributing to Fang and Ma’sresearch on the psychosocial, behavioral,and biological factors that may influencecancer risk. They are adding to what isknown about Asian-American populationswith striking health disparities, includingVietnamese-, Korean-, and Chinese-American women at high risk for cervicalcancer and Vietnamese-American menwith the hepatitis B virus (HBV), whichcontributes to nearly 80 percent of livercancer cases.

Fang and Ma’s teams have learned,for example, that while American-bornchildren are typically vaccinated againstHBV, Vietnamese immigrants—particularly uninsured, low-incomemales—often arrive in this countryalready infected and thus at high risk forliver cancer.

“I am confident that throughincreased awareness, appropriatescreening, vaccinations, and follow-upcare, we can reduce rates of cervical andHBV-related cancers,” says Fang.

For the good of the community

“The key is building trustingrelationships between communityleaders and research partners,” Fangadds. “We do our work where the peopleare—in churches, at festivals, and at thekitchen table. People have to trust thatwhat’s being done is for the good of thecommunity, and that kind of trustrequires transparency, education, and alot of discussion.”


Seeking HealtH equity Through service• Each year, more than 12,000

people attend free, bilingualcancer education eventspresented by Fox Chase’scommunity speakers bureau.

• Fox Chase’s mobile screeningunit, the only such unit in theregion, reaches underservedwomen with breast screening.

Through research• Fox Chase researchers are

probing the cultural, environ-mental, and biological reasonsbehind cancer disparities.

• Studies look at diseasepatterns such as cervicalcancer in Asian-Americanwomen and head and neckcancer in American blacks ofCaribbean origin.

“It is our hope that thiscomprehensive approach willyield health equity for theregion.”

- Evelyn Gonzalez, senior director, Fox Chase’s Office of HealthCommunications and Health

Disparities

MORE IS BETTER IN CLINICAL TRIALS


Left: Jean-Pierre Issa, MD, (left) and Patricia Kropf, MD, (right) review clinical trial results.Right: Henry C. Fung, MD, came to Fox Chase in January 2014 to lead the Center’s hematologic oncology program.

The Fox Chase-Temple affiliation means more clinical trials, and that’s better for patients.

Does the promising new result in thelab really confer more benefit thanstandard, accepted treatments? Clinicaltrials must answer this question beforea new treatment can come into broaduse. That is why Fox Chase has longfielded a strong array of clinical trials.

Now, through its affiliation withTemple University Health System, FoxChase can offer even more trials topatients, many in the area of hema -tologic oncology, a program that sawdramatic expansion and recruitment in2014. More trials mean more options forpatients with blood cancers such aslymphomas, leukemias, myeloma, andmyelodysplastic syndrome (MDS).

“Our affiliation with Temple hasresulted in an expanded clinical trialsprogram, providing novel therapies andunique drug combinations for patientswith hematologic malignancies,” saysPatricia Kropf, MD, director of the FoxChase-Temple MDS program. “Thathelps us succeed.”

Switching on the protection

The standard of care for mostpatients with MDS and Acute MyeloidLeukemia (AML) includes intensechemotherapy and/or a bone marrowtransplant, but older patients and thosewith additional medical problems oftencannot tolerate such a regimen. To find away to treat them, Kropf is collaboratingwith Jean-Pierre Issa, MD, a pioneer ofepigenetic research and chair ofTemple’s Fels Institute for CancerResearch and Molecular Biology. Theirapproach uses epigenetic therapy toreprogram cancer cells by reversingmethylation, the chemical process thatswitches off specific genes thatnormally protect cells from becomingcancerous.

In earlier research, Issa discoveredthat carboplatin and arsenic trioxide,two FDA-approved drugs long used totreat various malignancies, havehypomethylating properties. With thesedata as background, Kropf and Issa arenow exploring the safety and efficacy ofthese two drugs in combination withdecitabine, another hypomethylatingagent, for patients with MDS and AML.

Collaboration between Fox Chaseand Temple is nothing new for Kropfand Issa, who have worked together formore than three years. Where theaffiliation makes a difference is in thescale of their work and collaboration.They have recently been awarded theprestigious Stand Up to Cancer grant tofurther study and treat patients withhematologic malignancies.


it’S in our BloodLeadership• President and CEO Richard I.

Fisher, MD, a leader in thelymphoma field, has directedthe expansion of thehematologic oncology program.

• Henry C. Fung, MD, a nationallyrecognized figure in bloodcancers and bone marrowtransplant, arrived in January2014 to head the program.

Team effort• A team of recruits specializing

in hematologic malignanciescame on board in 2014.

• Fox Chase’s program workswith the Fox Chase-TempleBone Marrow TransplantProgram, which has performedmore than 1,500 transplants.

“Fox Chase’s amazing clinicaland basic science researchinfrastructure has enabled usto build our program into what Ithink will be one of the best inthe country.”

- Henry C. Fung, MD, director,hematologic oncology treatment team

and Fox Chase-Temple Bone MarrowTransplant Program

RESEARCH COLLABORATIONMEANS A WIN FOR PATIENTS


Elizabeth Plimack, MD, MS, (center and right) leads a multidisciplinary team studying treatment for muscle-invasive bladder cancer.

Genetic profiles predict which bladder cancer patients will see significant benefits from early chemotherapy.

Elizabeth R. Plimack, MD, MS, and hermultidisciplinary team think they mayhave hit a research jackpot withprofound implications for patients withinvasive bladder cancer. So far, theirresearch shows a strong correlationbetween certain genetic mutations andtreatment outcomes. “If our validationstudies confirm our initial results, we’llknow that patients carrying at least oneof three specific genetic mutations arelikely to respond to treatment, evenbefore surgery,” says Plimack. “Takingthe guesswork out of treatment choiceswould be a huge benefit to our patients.”

The standard treatment for muscle-invasive bladder cancer is radicalcystectomy, the surgical removal of thebladder and nearby organs. In Plimack’sstudy, 40 bladder cancer patients receivedan accelerated chemotherapy regimenbefore surgery, consisting of methotrexate,vinblastine, doxorubicin, and cisplatin(AMVAC). Two months later, at surgery,15 patients appeared cancer-free.

“We rarely see biomarkerdata this good.”

To uncover a genetic pattern thatwould predict responses to AMVAC,Plimack and her colleagues collaboratedwith Massachusetts-based FoundationMedicine to sequence a panel of cancer-related genes in tissue samples takenfrom 34 of these patients before theyunderwent chemotherapy. The analysisclearly landed on three genes associatedwith repairing damaged DNA. All but oneof the patients who benefited from theearly chemotherapy carried mutationsin at least one of three specific genes;none of these mutations were present inany of the people who still harboredtraces of cancer after AMVAC.

“Patients may have developed cancerin the first place because a damagedcell couldn’t repair itself. Once they havecancer, however, our hypothesis is thatthe defective DNA repair machinerymakes the tumor more likely to respond

to chemotherapy because the cancercells can’t repair the additional damagecaused by cisplatin,” says Plimack.

everyone contributesHer team was astonished to see

such a clear distinction between thegenetic profiles of responding and non-responding tumors. Plimack hastens tocredit her colleagues for lending theirdiverse expertise to the research:bioinformatics specialist Yan Zhou, PhD;biostatistician Eric Ross, PhD; molecularmodeling specialists Roland Dunbrack,PhD, and Mark Andrake, PhD; andmolecular therapeutics researchers EricaGolemis, PhD, and Ilya Serebriiskii, PhD.

“This collaboration is whattranslational medicine is all about,”affirms Plimack.


“Translation is crucial becauseit moves fundamentaldiscoveries in science intoclinical trials that we hope will positively impact patients.It takes concerted effort to see the potential clinical value of basic sciencedevelopments, and it takesactive collaboration betweenscientists and clinicians to act on that potential.”

– Wafik S. El-Deiry, MD, PhD, FACP, deputy cancer center director for

translational research

MAKING THE JOURNEY A LITTLE EASIER


Left: Patient Beth Brunswick (left) meets with her doctor Stephen Rubin, MD, (center) and nurse navigator Carol Cherry, MSN, RN (right).Right: Brunswick’s sister Julie Steinberg accompanies her to an appointment.

Nurse navigators collaborate with the whole Fox Chase care team to put patients’ health and comfort first.

One sunny Thursday afternoon, BethBrunswick, a 60-year-old New Yorker inFlorida with her husband, learned shehad ovarian cancer. She was stunned.“I’d never had major surgery,” saysBrunswick, “and here I was, a cancervictim out of the clear blue sky.”

Her gynecologist would recommendonly one physician—Stephen C. Rubin,MD, who at that very moment waspreparing to take the helm as chief ofgynecologic oncology at Fox Chase.

Brunswick flew to Philadelphia thatweekend. On Tuesday, with her husband,Ed Brunswick, her sister, Julie Steinberg,and her 88-year-old father, BenAlexander, she met with Rubin. By then,she had already spoken with CarolCherry, MSN, RN, a gynecologic oncologynurse navigator, who explained howthings would work, prepared thepaperwork, and gave Brunswick herdirect phone number. Rubin confirmedthe diagnosis and recommendedimmediate surgery.

“Let’s do it,” said Brunswick. “I wantthis cancer out of me.”

Rubin’s first week at Fox Chase wasfilled with orientation meetings, butCherry helped him rearrange hisschedule. Brunswick had her surgerythat Friday at 6 a.m.

Seven months later, Brunswick feelsfabulous—and grateful. “The people atFox Chase couldn’t be more wonderful.Carol Cherry made everything happensmoothly—she is so kind and capable—and Dr. Rubin, well, he’s the best. Everytime I see him, I give him a hug.”

Rubin and Cherry share Brunswick’senthusiasm for the collaborative,patient-friendly culture of Fox Chase.The only hospital in the regioncommitted to scheduling appointmentsfor new patients within one businessday of a call, Fox Chase is easilyaccessible, intimate, and approachable.“Our institutional commitment tocompassionate patient care is supportedfrom the very top,” says Rubin.

the most amazing journeyWith surgery completed, Cherry

continued to help Brunswick minimizethe disruptions that are inevitable withcancer treatment as much as she could.“Nurse navigators help patients connectthe dots between everything that’shappening inside Fox Chase and the restof their lives,” says Cherry. “We helpthem move forward.”

“I’m not finished with treatment, butI’m more than halfway through,” saysBrunswick. “Sure, there have been a fewbumps in the road, but my team at FoxChase has made this the most amazingjourney of my life.”


a SpeCial reSourCeFox Chase has been a leader in nurse navigationsince its program launchedfour years ago. • Today, the Center has 14 nurse

navigators specializing inbreast, gynecologic, thoracic,genitourinary, gastrointestinal,hematologic, and head andneck cancers, as well asmelanoma and sarcoma.

• Every nurse navigator is acertified oncology nurse,ensuring that patients can have urgent clinical questionsanswered quickly andaccurately.

“Navigators provide education,reduce barriers, and makeconnections for our patients so they arrive at their firstappointment knowing what toexpect and have less anxiety as they begin their cancerjourney.”

– Bonnie Miller, RN, BSN, OCN, FAAMA, administrator,

clinical nurse navigation

NEW PARTNERSHIP PROMISES BENEFITS FOR PATIENTS


Left: Jonathan Chernoff, MD, PhD, (left) and James Duncan, PhD, (right) work together on the new Cancer Kinome Initiative. Right: The kinome research is made possible by a gift from Don Morel, PhD, and his wife Lauren.

A recognized leader in kinase research, Fox Chase chief scientific officer JonathanChernoff, MD, PhD, knew that launching a Cancer Kinome Initiative could meansubstantial payoff for patients. Now he needed supporters to jump start the Initiativeuntil its work could mature to earn more external funding. In Don and Lauren Morel, hefound the perfect philanthropic partners.

Collectively known as the kinome, the518 human kinases are a group ofenzymes that are often co-opted bycancer cells to cause uncontrolledgrowth and invasion into surroundingtissues. While drugs that interruptkinase signals often induce remarkableshrinkage of tumors, over time thesetumors usually develop resistance tosuch agents and resume growth. Whatis needed is an effective method todetermine how cancer cells are“reprogrammed” to evade kinaseinhibitors.

Kinases have long been a focus forChernoff and his colleague Jeff Peterson,PhD. In 2013, James Duncan, PhD, joinedtheir team, a young scientist who isworking to establish a novel approach tomeasuring the activity of the entirekinome at a much greater and moreprecise level. This detailed informationwill show how tumors are responding totreatment so clinicians can adjust apatient’s drug regimen over time.

Hoping to organize this endeavor intoa formalized Initiative, Chernoff sought aphilanthropic partner. Don Morel, CEO ofthe highly successful West Pharma -ceutical Services, was a natural match.A PhD in materials science who has ledWest in developing novel pharma -ceutical technology, Morel was quick torecognize the value in galvanizing theCenter’s kinome research effort. He andhis wife Lauren pledged their support.

“Lauren and I were convinced by theunderlying science but also by JonChernoff’s enthusiasm for thetranslational potential,” says Morel, chairof the Fox Chase Foundation Board ofDirectors. “We are excited by thepossibility that this powerful scientificidea can work its way up from the lab tobenefit patients.”

Continuing supportThe Morels’ support for the Initiative

is the latest in a long line of generousgifts to Fox Chase. They have funded twoendowed chairs to support prominentFox Chase researchers, and each fall,dozens of West employees raise roughly$150,000 for Fox Chase at thePhiladelphia International Dragon BoatFestival.

“Now,” Chernoff says, “they aremaking possible a new and promisingapproach to tumor profiling that is notavailable elsewhere. Thanks to theMorels, Fox Chase is at the forefront ofthis work.”


driving innovationThe future of cancer caregrows brighter whenindividuals and familiesinvest in Fox Chase.Cancer Kinome Initiative. With a$1.5 million gift, Don and LaurenMorel are funding a novelapproach to measuring activityin kinases—enzymes thatregulate aspects of cell division.Patient Safety. Inspired by thequality of care at Fox Chase,Roberta and Ernest Schellergave $1 million in 2014 to helpimprove the field of patientsafety.

Gifts of All Sizes MatterSince Eileen Stein Jacobysuccumbed to breast cancer in1999, family and friends havecollectively raised more than$1.2 million for breast cancerresearch at Fox Chase.Learn more about givingto Fox Chase atfoxchase.org/HelpingFoxChase.

WITH THANKS


FounderS’ CirCle $500,000+Robert A. RitterJames J. WaltersAlfred P. West

CHairmen’S CirCle$100,000–$499,999Nancy M. Berman & Alan J. BlochCarol A. & Louis E. Della PennaEdmund M. DunnLee M. & Harvey GitlinDorrance H. HamiltonAgnes & James J. KimCynthia & Warren KrugerNaomi P. & Philip E. LippincottLauren & Donald E. Morel Jr.Roberta R. & Ernest SchellerJames M. SmithMayya StezherenskayaFrances H. Vance

advoCateS’ CirCle $25,000–$99,999Betty Ann & R. Reginald BishopElla B. CummingsWarren W. CunninghamSusan C. & William J. FedericiCatherine R. & Peter E. GetchellKay & Thomas W. HofmannAurora M. & Timothy P. Hughes

George R. James Sr.Margot Wallace Keith & Robert E. KeithEdwin M. LavinoMary Alice MaloneLouise S. MauranPatricia A. & Bruce A. Ruggeri Albina M. ScheelDebra T. & Leo M. Sniger

CHampionS’ CirCle$10,000–$24,999AnonymousAlice C. BassettCindy & Jack BienenfeldHelen B. BienenfeldMichael BienenfeldLucy S. BinderJohn M. CacceseTheresa R. ClaytonReina S. & Michael A. CohenKathleen M. & Larry K. CordellLinda & Robert DevlinJoan M. & John A. DietzeVirginia W. DunnGloria E. & Steven A. EllersLori Emrick & Todd J. GlassmanJanet F. & Paul F. EngstromFrancis S. FenstermacherSusan G. & Richard I. FisherSherry & Geoffrey GallowayDoris & Arnold GlabersonDiana Keat & Edward A. Glickman

Elaine E. & Michael K. HeadleyLynn & Brian HochbergElizabeth H. & James A. KilduffStephanie A. King & Paul G. CurcilloGeorgia B. & Richard W. KoenigJane M. & Kenneth B. LaffendWilliam H. LambertJudith & Thomas K. LeidyJeanne S. LeinenBonnie K. & Bruce S. MarksSandra G. & David G. MarshallJoseph W. McCloskeyAnna T. Meadows & Alfred G. Knudson Jr.Salli & Stephen R. MickelbergRichard B. MillhamLee & Paul O'HaganLynne S. & Daniel W. RayMary D. & Edward J. RoachDebbie & Arthur A. RoedelHara & Todd SalkovitzSusan F. & Andrew R. TaussigJane & Robert TollCarol J. & Stephen E. Young

guardianS’ CirCle$5,000–$9,999Michele AnthonyEllen G. & Michael E. AratenGerald F. ArlethMyra J. & E. Boyd AsplundhErika L. AustinSharon & William J. Avery

Maggie & Bob BeckAmy A. Pruitt & Andrew G. BodnarJaclyn L. & Robert BrunoLizbeth A. & Ed BrunswickJanet D. & Eli J. CaplanMaureen A. & Gregory A. ChurchElaine M. DanielsLowell H. DubrowDeirdre A. & Anthony EhingerAlice B. Erber & Robert SteinbergNancy T. FinneganAmy R. & Jon S. FisherJoEllen & John R. Gailey IIIFrank R. GianforteNancy E. GoldyMarion & Emanuel GolemisTheresa M. & John R. GreedElaine I. & Sidney GrobmanDiane T. & Robert J. HansberryBrunhilde H. & John J. HopkinsonRenee L. & Jeffrey C. HuntBarbara R. & Charles Kahn Jr.Val & Allen KanterNicole T. & Kenneth KleinLaura H. LeinenMichelle LudwigWendy H. & Solomon C. LuoBetty & Richard D. LuzziDiane S. & Christian F. MartinGinny & John McDonaldDavid R. McShaneKathleen & Francis X. Morris


Jessica L. & Kevin NealeCheryl E. & Robert A. NeubertLisa James Otto & Jonathan E. OttoDoreen H. PayntonSuzanne Perrault & David RagoAnn L. & Frank E. ReedSylvia E. & Paul E. SchneiderGeraldine F. SteinbergThomas M. SteinbergRuth WeberSusan & James WrightLorraine A. Zacierka

CorporationS, FoundationS, & organizationSAetna FoundationAHEPA Cancer Research Foundation,

Fifth DistrictAmy’s FundAsbestos.comAvery FoundationThe Morris S. & Florence H. Bender

FoundationPhilip & Muriel Berman FoundationThe Henry and Helen Bienenfeld

FoundationBig TippersBoard of Associates of

Fox Chase Cancer CenterBucks County ChapterThe Devlin Fund for Cancer ResearchMarlyn R. Fein Chapter

Fox Chase ChapterFriends of the HospitalJimbo’s SquadThe Trading Post

Breast Cancer Relief FoundationBroughton FoundationCakeman’s CrewCanyon Ranch Health & Fitness CenterJulius H. Caplan Charity FoundationE. Rhodes & Leona B. Carpenter

FoundationCelgeneChain Reaction for a CureTess Clayton Charities Inc.The Cordell Family FoundationThe Curcillo King Family FoundationCut for the Cure, Inc.C.W.A. Local 13000The Dana FoundationDigital Science Press Inc.The Marianne DiNofrio Pancreatic Cancer

Research FoundationThe William & Susan Federici

Charitable FundConstance and Carl Ferris Charitable

Operating FoundationFoundation for Breast and Prostate HealthFourjay FoundationFoxdragonsThe Walter Henry Freygang FoundationGenentech, Inc.The George Snyder Memorial FundThe Frank and Dale Gianforte

Charitable Fund

J. Roland Gilbert, Mary R. Gilbert andElizabeth A. Gilbert Memorial Fund

GIST Cancer Research FundThe Harvey S. Gitlin Family FoundationGlassman Family FoundationThe Hilferty Memorial Golf TournamentThe Hofmann Family FundRita R. Holman

Breast Cancer Foundation Inc.ING FoundationInsulators & Allied Workers Local #14Insulators Industry Promotion FundOscar H. & E. Ida Iucker Memorial FundThe Eileen Stein Jacoby FundJohnson & JohnsonBarbara R. Kahn & Charles Kahn Jr.

Foundation Inc.The Kanter FoundationThe Kicking Cancer FoundationKilduff Family FoundationThe James & Agnes Kim Foundation, Inc.The Richard J. Kruger FoundationThe LaForgia Redington Golf ClassicL.A.O.H. Brigid McCrory Division 25Eli Lilly & CompanyLutron FoundationMag Pitt, LPThe Malfer FoundationNancy Peery Marriott FoundationThe McGrorty Foundation, Inc.McNeil Consumer HealthcareMerck Partnership for GivingMerrill Lynch

Mickelberg Family FoundationMillennium Pharmaceuticals, Inc.The Muscari Family Partnership, L.P.Mutual of America FoundationNational Breast Cancer FoundationNeshaminy School DistrictNorristown Bocce LeagueNovartis Pharmaceuticals CorporationNY-NE States Golf CharityTyanna Barre O'Brien Breast Cancer

FoundationThe Philadelphia FoundationThe Roemer FoundationSandy Rollman Ovarian Cancer FoundationCharles Schwab Corporation FoundationShui LongThe W. W. Smith Charitable TrustThe Sniger Family Charitable FundIsabella P. Spratt FundTeal Ribbon Ovarian Cancer

Research FoundationTeal Tea FoundationRobert & Jane Toll FoundationUkrainian American Sports CenterUnited Way AgenciesUnivest FoundationRuth & Alfred Weber Family FoundationWest DragonPhyre & DragonPhlameThe H. O. West FoundationWest Pharmaceutical Services, Inc.Wheels of Wellness, Inc.Wright-Cook Foundation

Fox Chase Cancer Center is very grateful to our supporters for their commitment to our mission and the resources that give us an extra edge toward excellence. Thank you.


research Snapshot

active Funded projectsFunding Source Number of Projects Direct Costs Total Costs

PEER-REvIEWED

NCI 102 $13,326,571 $21,730,136

Other NIH 53 8,772,135 14,516,269

Other 30 3,011,219 4,043,714

Subtotal of peer-reviewed 185 $25,109,925 $40,290,119

NON-PEER-REvIEWED

Industry 43 $3,893,689 $5,022,859

Other non-peer-reviewed 35 2,547,829 2,958,033

Subtotal of non-peer-reviewed 78 $6,441,518 $7,980,892

grand total 263 $31,551,443 $48,271,011

394Total Number of

Active Clinical Trials

328Total Number of

Active Treatment Trials

2014 FINANCIALSphilanthropy Snapshot

20% increase in total philanthropic support

$16.9 million total philanthropic support

$260,000 raised at the inaugural In Vino Vita wine auction event

788 current donors who have been giving for 30 or more years

273 members of the Elizabeth AndersonSociety, celebrating donors who havemade a planned gift for long-termsupport of the Center

47 donors who have been members of the Laurel Society, celebrating annual gifts of $1,000 or more, since its inception in 2009

volunteer Snapshot

540 volunteers

118,047 total volunteer hours;

equivalent to 60.53 full-time employees

$204,754 volunteer department budget

$2,661,950 value of hours,

measured by Independent Sector

Rate ($22.55)

$2,457,206 net value added

to Fox Chase

Numbers represent Fiscal Year 2014


Clinical Snapshot(in thousands)

FY14

REvENuES - CLINICAL ACTIvITY

Patient Care Revenue - Hospital $244,966

Patient Care Revenue - Physicians 31,420

Philanthropy, Outreach & Other 12,274

Clinical revenue $288,660

OPERATING ExPENSES - CLINICAL ACTIvITY

Direct Patient Care $214,669

Administrative and General 40,937

Capital Related Costs 12,687

Maintenance and Plant Operations 12,498

Clinical expenses $280,791

KEY PATIENT CARE STATISTICS

New Patients 7,599

Hospital Admissions 4,756

Outpatient Registrations 43,361

Chemotherapy Infusions and Related Procedures 45,563

Radiation Therapy Treatments 22,204

Fy14 payer mix

Medicare Managed Care 9%

Medicaid 4%

Medicare 33%

Commercial 50%Other 4%

types of Cancer

treated

3%4% 4%

5% 5%

7%8%

10%11% 11%

15%

17%

Colo

rect

al

Pros

tate

Bre

ast

Gyn

ecol

ogic

Lung

Oth

er

Lym

phom

a

Panc

reat

ic

Hea

d an

d N

eck

Skin

Bla

dder

Kid

ney


LEADERSHIP & FACULTY Senior adminiStratorSrichard i. Fisher, mdPresident and Chief Executive OfficerCancer Center Director Senior Associate Dean, Temple University

School of Medicine

J. robert Beck, mdDeputy Cancer Center Director Chief Academic Officer Chief Administrative Officer

Jonathan Chernoff, md, phdDeputy Cancer Center DirectorChief Scientific Officer

Wafik S. el-deiry, md, phd, FaCpDeputy Cancer Center Director for

Translational Research

Judith l. Bachman, rn, BSn, mSn, CnaaChief Operating Officer

anthony diasio, Cpa, mBaChief Financial Officer

James Helstrom, md, mBaChief Medical Officer

anne Jadwin, rn, mSn, aoCn, ne-BCChief Nursing Officer

rich SantoroInterim Chief Development Officer

Fox CHaSe CanCerCenter FoundationBoard oF direCtorSChair: Donald E. Morel Jr., PhDvice Chair: Louis E. Della Penna Sr.

Frank G. Binswanger Jr.Richard I. Fisher, MDEdward A. GlickmanNancy E. GoldyLewis F. Gould Jr.Thomas W. HofmannLawrence T. Hoyle Jr., Esq.Margot W. KeithGeoffrey KentPhilip E. Lippincott Solomon C. Luo, MDDavid G. MarshallEdward J. RoachThomas E. Shenk, PhDLindy SniderDebra SnigerWilliam StulginskyThomas R. Tritton, PhD

Staff MembersJudith L. BachmanJ. Robert Beck, MDLisa CorbinAnthony DiasioCarmel VaheyNina Weisbord

ameriCan onCologiCHoSpital Board oFdireCtorSChair: Lewis F. Gould, Jr.J. Robert Beck, MDJohn M. Daly, MDVerdi J. DiSesa, MDRonald R. DonatucciEdward A. GlickmanLon R. GreenbergKimberly D. HagerichThomas W. HofmannLarry R. Kaiser, MDMargot W. KeithRobert H. LeFeverSolomon C. Luo, MDDavid G. MarshallChristopher W. McNicholDonald E. Morel Jr., PhDLeon O. Moulder, Jr.Thomas E. Shenk, PhD

Fox CHaSe CanCerCenter endoWed CHairSlouiS della penna Family CHairin Head and neCk onCology John A. Ridge, MD, PhD, FACSVice Chair, Surgical Oncology

Carol and louiS della pennaCHair in urologiC onCology Richard Greenberg, MD, FACSChief, Urologic Oncology

tHe gloria and edmund m. dunnCHair in tHoraCiC SurgiCalonCologyWalter J. Scott, MD, FACS Chief, Thoracic Surgery

marvin S. greenBerg, md, CHairin panCreatiC CanCer SurgeryJohn P. Hoffman, MD, FACS Chief, Pancreaticobiliary Service

paul grotzinger and WilBurraaB CHair in SurgiCal onCologyStephen C. Rubin, MD Chief, Gynecologic Oncology

tHe Samuel m.v. Hamilton CHairin CanCer prevention Paul F. Engstrom, MD Acting Chair, Medical Oncology

gerald e. HankS CHair inradiation onCologyEric M. Horwitz, MD Chair, Radiation Oncology

g. Willing “Wing” pepper CHair inCanCer reSearCH Robert G. uzzo, MD, FACS Chair, Surgical Oncology

Stanley p. reimann CHair inonCology reSearCHJonathan Chernoff, MD, PhD Chief Scientific Officer


JaCk SCHultz CHair in BaSiCSCienCeBeatrice Mintz, PhDProfessor, Cancer Biology

timotHy r. talBot Jr. CHair inCanCer reSearCH Mary B. Daly, MD, PhD, FACP Chair, Clinical Genetics

audrey Weg SCHauS & geoFFreyalan Weg CHair in mediCalSCienCeDavid S. Weinberg, MD, MScChair, Department of Medicine

Carol and kennetH Weg CHair inHuman genetiCSJoseph R. Testa, PhD Co-Leader, Cancer Biology

H.o. WeSt and J.r. Wike CHair inCanCer reSearCHJ. Robert Beck, MDChief Academic and Administrative Officer

William WikoFF SmitH CHair inCanCer reSearCH Anna M. Skalka, PhDBasic Science Director Emerita

roBert C. young, md CHair inCanCer reSearCHJeff Boyd, PhD Professor, Cancer Biology

pending appointmentS:G. Morris Dorrance Jr. Chair in Medical OncologyAlfred G. Knudson Jr. Chair in Basic ScienceDonald E. and Shirley C. Morel, Stanley

and Stella Bayster Chair in Molecular Imaging

CliniCal FaCultydepartment oF CliniCalgenetiCS Chair: Mary B. Daly, MD, PhDMichael J. Hall, MDElias Obeid, MD

department oF diagnoStiCimaging Chair: Rosaleen B. Parsons, MDJesty Abraham, DOMarion Brody, MDMark Burshteyn, MD1

Gary Cohen, MD1

Emily Cuthbertson, MD1

Kristin Edwards, MDKathryn Evers, MDMarlane Guttmann, MDBarton N. Milestone, MDDmitry Niman, MD1

Joseph Panaro, MD1

David Pryluck, MD1

Catherine Tuite, MDRohit Walia, MDJian Q. Yu, MD

department oF mediCalonCology Acting Chair: Paul F. Engstrom, MD David E. Adelberg MD2

Igor Astsaturov MD, PhD Stefan K. Barta, MDMarijo Bilusic, MD, PhD Hossein Borghaei, DO Yanis Boumber, MD, PhD

Robert W. Carlson, MD Jonathan D. Cheng, MD Steven J. Cohen, MD Crystal S. Denlinger, MD Efrat Dotan, MD Scot W. Ebbinghaus, MD Wafik S. El-Deiry, MD, PhDRichard I. Fisher, MD Henry C. Fung, MD Daniel M. Geynisman, MD Lori J. Goldstein, MD Gary R. Hudes, MD Angela Jain, MD Nadia Khan, MD Patricia L. Kropf, MD Michael H. Levy, MD, PhD Gregory M. Lubiniecki, MD Lainie P. Martin, MD Mary Ellen Martin, MD Ranee Mehra, MD Michael M. Millenson, MD Juhi Mittal, MD Sujana Movva, MD Anthony J. Olszanski, MD, RPh Aruna Padmanabhan, MD Alvaro Pereira-Rico, MD Elizabeth R. Plimack, MD Vijay Sandilya, MD2

Deric C. Savior, MD Jennifer Y. Shih, MD Joseph Treat, MD Margaret von Mehren, MD Yu-Ning Wong, MD

pain and palliative CareMarcin Chwistek, MD Michael H. Levy, MD, PhD

department oF mediCineChair: David S. Weinberg, MD

CardiologySteven J. Mattleman, MD

dermatologyClifford S. Perlis, MD Anthony Santoro, MD

endoCrinologyColleen Veloski, MD

gaStroenterologyStephen J. Heller, MD Minhhuyen T. Nguyen, MD Jeffrey L. Tokar, MD David S. Weinberg, MD

HoSpitaliSt ServiCeRichard F. Dietrick, MDDaniel K. Holleran, MDKyungsuk Jung, MDMala T. Kailasam, MDManjula Sharada Naik, MDKenneth P. Patrick, MD

pHySiCal mediCine andreHaBilitationGilbert Lafontant, MD

pSyCHiatryKaren Y. Mechanic, MD Emmie I. Chen, MDMichelle Rodoletz, PhD

pulmonary mediCineAlan D. Haber, MD Earl King, MD Pramod Krishnamurthy, MD Rohit Kumar, MD


FACULTYdepartment oF patHologyChair: Arthur S. Patchefsky, MDEssel D. Al-Saleem, MD Tahseen I. Al-Saleem, MD Harry S. Cooper, MD Hormoz Ehya, MD Douglas B. Flieder, MD Karen S. Gustafson, MD, PhD Min Huang, MD, PhD Valentin G. Robu, MD, PhD Hong Wu, MD, PhD

department oF radiationonCologyChair: Eric M. Horwitz, MD Penny R. Anderson, MD Jo Ann Chalal, MD Thomas J. Galloway, MD Mark A. Hallman, MD, PhD Shelly B. Hayes, MD C-M Charlie Ma, PhD Joshua E. Meyer, MD Lawrence J. Scharf, MD3

Charu Sharma, MD4

Mark L. Sobzcak, MD Stephanie E. Weiss, MD

department oF SurgiCal onCologyChair: Robert G. Uzzo, MD Cynthia A. Bergman, MD Richard J. Bleicher, MD Marcia Boraas, MD Eric I. Chang, MD David Y. T. Chen, MD Christina S. Chu, MD Paul G. Curcillo II, MD John Daly, MD Nestor F. Esnaola, MD Jeffrey M. Farma, MD Christopher Fundakowski, MD Richard E. Greenberg, MD John A. Handal, MD John P. Hoffman, MD Andreas Karachristos, MD Stephanie A. King, MD Alexander Kutikov, MD Miriam N. Lango, MD Jeffrey C. Liu, MD Gina M. Mantia-Smaldone, MD Sameer A. Patel, MD Sanjay S. Reddy, MD

John A. Ridge, MD, PhD Stephen C. Rubin, MD Walter J. Scott, MD Prashant C. Shah, MD Elin R. Sigurdson, MD, PhD Marc C. Smaldone, MD Stacey Su, MD Neal S. Topham, MD Rosalia Viterbo, MD Michael Weaver, MD

aneStHeSiologyPhillip Carroll, MD Tanveer K. Chaudhry, MD James L. Helstrom, MDBasil Karayannis, MD Kristin K.G. Krauss, MD Ann Lovitt, MD Flore Macenat, MD Michelle McMaster, MD Howard Schwartz, DO Imran Sharaf, MD Mahmood Siddique, MD Murray Suskin, MD

1 Member of the Temple University HealthSystem Interventional Radiology team

2 Attending Physician, AtlantiCare CancerCare Institute, Cape May Courthouse andEgg Harbor Township, NJ

3 Attending Physician, Academic UrologyProstate Center, King of Prussia, PA

4 Attending Physician, Virtua Fox ChaseCancer Center Radiation Oncology,Washington Township, NJ

reSearCH FaCultyBlood Cell development andFunCtionprogram leaderSGlenn F. Rall, PhDDavid L. Wiest, PhD

primary memBerSTahseen I. Al-Saleem, MD1

Siddharth Balachandran, PhD Michael E. Bromberg, MD, PhD2

Kerry S. Campbell, PhD Richard I. Fisher, MD1

Stefania Gallucci, MD2

Doina Ganea, PhD2

Richard R. Hardy, PhD Kyoko Hayakawa, MD, PhD Barbara Hoffman, PhD2

Dietmar J. Kappes, PhD Ekaterina Koltsova, PhDDan A. Liebermann, PhD2

Jennifer Rhodes, PhD Valentin Robu, MD, PhD Christoph Seeger, PhD Luis J. Sigal, DVM, PhD Ann Skalka, PhD Tomasz Skorski, MD, PhD, DSc2

Jonathan Soboloff, PhD2

Stephen M. Sykes, PhDRaza M. Zaidi, PhD2

CanCer Biologyprogram leaderSJonathan Chernoff, MD, PhDJoseph R. Testa, PhD


primary memBerSPatnala Mohanrao Achary, PhD2

Raghbir S. Athwal, PhD2

Jeff Boyd, PhD Edna Cukierman, PhD James S. Duncan, PhD Mark A. Feitelson, PhD2

Omar Z. Fisher, PhD2

Lawrence E. Goldfinger, PhD2

Jennifer Gordon, PhD2

Xavier Graña, PhD2

Raymond Habas, PhD2

Gary R. Hudes, MD1

Andres J.P. Klein-Szanto, MD, PhD Vladimir Kolenko, MD, PhD Warren D. Kruger, PhD Alexander Kutikov, MD1

Peter I. Lelkes, PhD2

Biao Luo, PhD Beatrice Mintz, PhD Alana O’Reilly, PhD Jeffrey R. Peterson, PhD Richard T. Pomerantz, PhD2

Victor Rizzo, PhD2

Fabrice Roegiers, PhD Jose Russo, PhDDianne R. Soprano, PhD2

Alexei V. Tulin, PhD Robert G. Uzzo, MD1

Slobodan Vucetic, PhD2

Hong Yan, PhD Zeng-jie Yang, MD, PhD Tim J. Yen, PhD

moleCular tHerapeutiCSprogram leaderSWafik S. El-Deiry, MD, PhD1

Erica A. Golemis, PhD

primary memBerSMagid Abou-Gharbia, PhD2

Gregory P. Adams, PhD Rodrigo Andrade, PhD2

Oneida A. Arosarena, MD2

Igor Astsaturov, MD, PhD1

Hossein Borghaei, DO1

Yanis Boumber, MD, PhD1

Lili Chen, PhD Steven J. Cohen, MD1

Denise C. Connolly, PhD Mohan Doss, PhD Roland L. Dunbrack Jr., PhD Brian L. Egleston, PhD James S. Ferriss, MD2

Lori J. Goldstein, MD1

Elizabeth Hopper-Borge, PhD Eileen K. Jaffe, PhD Neil Johnson, PhD Michael L. Klein, PhD2

Sudhir Kumar, PhD2

Ronald Levy, PhD2

Jeffrey C. Liu, MD1,2

C-M Charlie Ma, PhD1

Lainie P. Martin, MD1

Ranee Mehra, MD1

Salim Merali, PhD2

Bizhan Micaily, MD2

Curtis Miyamoto, MD2

Anthony J. Olszanski, RPh, MD1

John A. Ridge, MD, PhD1

Lori Rink, PhD Matthew Robinson, PhD Heinrich Roder, PhD Elin R. Sigurdson, MD, PhD1

Byungse Suh, MD, PhD2

Vincent A. Voelz, PhD2

Margaret von Mehren, MD1

Ho-Lun Wong, PhD2

Jinhua Wu, PhD William M. Wuest, PhD2

Jian Qin Yu, MD2

CanCer prevention and Controlprogram leaderSMargie L. Clapper, PhDCarolyn Y. Fang, PhD

primary memBerSSarah Bauerle Bass, PhD2

J. Robert Beck, MD Bradley N. Collins, PhD2

Mary B. Daly, MD, PhD1

Paul F. Engstrom, MD1

Nestor F. Esnaola, MD1,2

Susan Gross Fisher, PhD2

Ana M. Gamero, PhD2

Sergei Grivennikov, PhD Michael J. Hall, MD1

Carolyn J. Heckman, PhD Enrique Hernandez, MD2

Stephen L. Lepore, PhD2

Grace X. Ma, PhD2

Suzanne M. Miller, PhD Swati Nagar, PhD2

Deborah B. Nelson, PhD2

Camille Ragin, PhD Kathleen J. Reilly, MD2

Laura Siminoff, PhD2

Ellen Ann Walker, PhD2

David S. Weinberg, MD1

Kuang-Yi Wen, PhD Yu-Ning Wong, MD1

CanCer epigenetiCSprogram leaderSJean-Pierre J. Issa, MD2

Vasily M. Studitsky, PhD

primary memBerSAndrew J. Andrews, PhD Alfonso Bellacosa, MD, PhD Paul Cairns, PhD Xiaowei Chen, PhD Nora Engel, PhD2

Jian Huang, MD, PhD2

Jaroslav Jelinek, MD, PhD2

Richard A. Katz, PhD Patricia L. Kropf, MD1

Elizabeth Plimack, MD1

Carmen Sapienza, PhD2

Bassel E. Sawaya, PhD2

Italo Tempera, PhD2

Hong Wang, MD, PhD2

Alliric I. Willis, MD2

Yi Zhang, MD, PhD2

1 Member of the Fox Chase Cancer Centerclinical faculty

2 Faculty based at Temple University

First Last Name

123 Any Street

Suite ABC

Any Town, PA 19000

333 Cottman Ave.Philadelphia, PA 19111-2497

www.foxchase.org1-888-FOX-CHASE

“Scientists and clinicians make their most meaningful contributions to advancing cancer care when they work together as a team.”

–Richard I. Fisher, MD, President and CEO

Connect with us online! Visit, pubweb.fccc.edu/annualreport

A NEW ERA...Fox Chase President and CEO Richard I. Fisher, MD, (third from left) prepares for a day in the clinic with his hematologic oncology team. Since Richard I. Fisher, MD, took

Documents